The relevant distinction between "progression" in ovarian cancer drug trials and the clinical decision to change therapy.
我要评论
本期排行
- Association of diffuse, random...
- Intra-arterial chemotherapy fo...
- New data on BRCA mutations and...
- Association of multi-drug resi...
- Radiofrequency ablation as an ...
- Low triglyceride and nonuse of...
- Short duration of sleep increa...
- Overexpression of receptor tyr...
- Prognostic model for survival ...
- The relevant distinction betwe...
共0条评论